Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We evaluated the effect of empagliflozin as adjunct to insulin on 24-h glucose exposure and variability in patients with type 1 diabetes.

Related collections

Author and article information

Journal

PubMed ID:: 27929674

DOI:: 10.1089/dia.2016.0261

Keywords: Hypoglycemia,Type 1 diabetes,Postprandial blood glucose,Hyperglycemia,Continuous glucose monitoring,HbA1c

Data availability:

Keywords: Hypoglycemia, Type 1 diabetes, Postprandial blood glucose, Hyperglycemia, Continuous glucose monitoring, HbA1c

Comments

Comment on this article

scite_

Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).

Read this article at

Universal stem cells

Journal

Comment on this article